AVAMMUNE THERAPEUTICS
Avammune Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Avammune is developing a multimodal approach to modulate the STING pathway to treat cancer. Their multimodal approach employs a combination of engineered viruses and small molecules.
AVAMMUNE THERAPEUTICS
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2017-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.avammune.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Indian Server Location
Similar Organizations
Aracari Biosciences
Aracari is a Drug discovery company.
Cero Therapeutics
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
Delix Therapeutics
Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
Evariste Technologies
Biotech using quantitative modelling to make drug discovery more efficient
Filament Health
Filament Health is a natural psychedelic extraction and drug discovery company
Innopharmascreen
Innopharmascreen is a ICT based drug discovery company.
KAICO
KAICO is a pharmaceuticals, diagnostic drugs production company.
Orthogon Therapeutics
Orthogon Therapeutics is a drug development company.
Pleryon Therapeutics
Pleryon Therapeutics is a drug delivery platform company.
Current Advisors List
Current Employees Featured
Founder
Investors List
The Chennai Angels
The Chennai Angels investment in Venture Round - Avammune Therapeutics
Official Site Inspections
http://www.avammune.com Semrush global rank: 15.27 M Semrush visits lastest month: 14
- Host name: md-in-89.bigrockservers.com
- IP address: 119.18.58.248
- Location: India
- Latitude: 20.0063
- Longitude: 77.006
- Timezone: Asia/Kolkata
More informations about "Avammune Therapeutics"
Avammune Therapeutics
Avammune Therapeutics is a small molecule drug discovery and development company developing modulators of the innate immune system. Avammune’s approach integrates novel target biology and immunology, computational …See details»
Avammune Therapeutics - Crunchbase Company …
Avammune Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Avammune is developing a multimodal approach to modulate the STING pathway to treat cancer. Their …See details»
Avammune Therapeutics Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Avammune Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Avammune Therapeutics - LinkedIn
Avammune Therapeutics is a drug discovery company focused on the development of novel immunotherapeutics to address high unmet medical needs. Our research is driven by the …See details»
Avammune Therapeutics - Company Profile - Tracxn
Nov 29, 2024 Avammune Therapeutics - Developer of non-nucleotidic small molecule inhibitors for the treatment of cancer and auto-immune diseases. Raised funding over 3 rounds from 2 …See details»
Avammune Therapeutics - Contacts, Employees, Board Members, …
Avammune Therapeutics has 2 current employee profiles, including Founder and Chief Scientific Officer Aditya Kulkarni. Avammune Therapeutics has 4 board members and advisors, …See details»
Avammune Therapeutics - Overview, News & Similar companies
View Avammune Therapeutics (www.avammune.com) location in United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Avammune Therapeutics - Funding, Financials, Valuation & Investors
Jul 15, 2022 Avammune Therapeutics has raised 2 rounds. Their latest funding was raised on Jul 15, 2022 from a Venture - Series Unknown round. Avammune Therapeutics is funded by …See details»
Avammune Therapeutics - VentureRadar
"Avammune Therapeutics Inc. (formerly known as Straximm Therapeutics), a spin-off from Aten Porus Lifesciences (Bangalore, India), is developing highly potent and specific small molecule …See details»
Avammune Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Avammune Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 literature, Disease Domain:Neoplasms, Technology Platform:Small ...See details»
Avammune Therapeutics - Craft
Avammune Therapeutics (formerly Straximm Therapeutics) is a drug discovery company focused on cancer immunotherapy. It develops non-nucleotidic small molecules inhibitors of …See details»
Arun B Papaiah - Avammune Therapeutics | LinkedIn
- Business Development, Finance, Recent Milestone - Oraxion Therapeutics, Inc., executes… · Experience: Avammune Therapeutics · Location: Bengaluru · 500+ connections on LinkedIn. …See details»
GEO Accession viewer - National Center for Biotechnology …
Apr 17, 2023 NCBI's Gene Expression Omnibus (GEO) is a public archive and resource for gene expression data.See details»
Avammune Therapeutics Announces Series A Funding and …
Jul 9, 2019 Avammune Therapeutics Inc., (formerly known as Straximm Therapeutics), a spin-off from Aten Porus Lifesciences (Bangalore, India), today announced the raise of its Series A …See details»
Avammune Therapeutics, Inc. (Avammune Therapeutics, Inc.) - 药 …
了解Avammune Therapeutics, Inc. (Avammune Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1篇文献，疾病领域:肿瘤，技术平台:小分子化药，化学药，药物:AVA …See details»
Avammune Therapeutics Announces Series A Funding and …
Jul 9, 2019 Avammune Therapeutics Inc., is a drug discovery company focused on the development of systemically administered small molecule modulators of the STING pathway to …See details»
Research programme: immuno oncology therapeutics
Small molecule therapeutics are being developed by Avammune Therapeutics (a spin-off from Aten Porus Lifesciences) for the treatment of solid tumours. EarlySee details»
Aten Porus raises pre-series round lead by JITO Angel Network
The funding will help advance Avammune’s highly diversified pipeline of best-in-class and first-in-class assets for oncology and autoimmune disorders Avammune Therapeutics (a spin-off from …See details»
AVA NP 695 - AdisInsight
AVA NP 695, a orally administered small molecule, is being developed by Avammune Therapeutics (a subsidiary of Aten Porus Lifesciences) for the treatment ofSee details»
1334 AVA-ADR-001 supresses tumor growth and induces anti …
1334 AVA-ADR-001 supresses tumor growth and induces anti-tumor immunity by selectively inhibiting ADAR1 p150See details»